Peptide Mapping by Liquid Chromatography-Mass Spectrometry (LC-MS)

Peptide mapping generates a detailed peptide “fingerprint” used to confirm a protein’s primary amino acid sequence and to identify and monitor its post-translational modifications (PTMs).

• Legacy Techniques: Early 2D chromatography or HPLC-UV methods followed by slow, sequential Edman degradation.

• Established Standard: Reversed-phase HPLC or UPLC coupled to high-resolution mass spectrometry (HRMS), such as an Orbitrap or Q-TOF instrument.

• Emerging Alternatives: Multi-Attribute Methods (MAM), which leverage a single LC-MS assay to simultaneously monitor multiple Critical Quality Attributes (CQAs).

A protein is denatured and enzymatically digested, typically with trypsin. The resulting peptides are separated by reversed-phase LC based on their hydrophobicity. As peptides elute, they are ionized (e.g., by ESI) and their mass-to-charge ($m/z$) ratios are measured by the mass spectrometer to confirm their identity and detect modifications.

• Analysis involves matching experimental peptide masses from the LC-MS run to a theoretical (in silico) digest of the expected amino acid sequence.

• A high percentage of sequence coverage (e.g., >95%) with low mass error (e.g., < 5 ppm) for matched peptides confirms identity. Unexpected masses on specific peptides indicate potential modifications.

• Provides amino acid-level structural detail.

• Serves as a definitive identity confirmation test.

• Enables comprehensive PTM detection and localization.

• Offers high sensitivity for detecting low-level modifications.

• Complex sample preparation (digestion) can introduce artifacts, such as artificial oxidation.

• Incomplete sequence coverage may occur if certain peptides have poor chromatographic behavior or ionization efficiency.

• Relative quantification of PTMs can be challenging; high accuracy may require isotopic labeling

• Achieving consistent and high sequence coverage.

• Demonstrating the ability to detect critical PTMs, often confirmed using artificially stressed samples.

• Reproducibility of the peptide chromatogram and the profile of identified modifications.

• mAbs & Proteins: A mandatory identity test used to monitor critical PTMs like oxidation and deamidation and to confirm all disulfide bonds.

• ADCs & Conjugates: Identifies the specific sites of drug conjugation on the antibody and helps characterize the drug-load distribution.

• Vaccines: Confirms the identity and integrity of recombinant protein antigens within a vaccine formulation.

• Gene Therapy (AAVs): Can be used as a deep characterization tool to confirm the full amino acid sequence of the constituent capsid proteins (VP1/VP2/VP3), but it is less common as a routine identity test compared to intact protein analysis or SDS-PAGE.